GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flexion Therapeutics Inc (NAS:FLXN) » Definitions » Inventories, Raw Materials & Components

Flexion Therapeutics (Flexion Therapeutics) Inventories, Raw Materials & Components : $2.8 Mil (As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Flexion Therapeutics Inventories, Raw Materials & Components?

Flexion Therapeutics's inventories, raw materials & components for the quarter that ended in Sep. 2021 was $2.8 Mil.

Flexion Therapeutics's quarterly raw materials declined from Mar. 2021 ($4.4 Mil) to Jun. 2021 ($3.6 Mil) and declined from Jun. 2021 ($3.6 Mil) to Sep. 2021 ($2.8 Mil).

Flexion Therapeutics's annual raw materials increased from Dec. 2018 ($2.4 Mil) to Dec. 2019 ($2.8 Mil) and increased from Dec. 2019 ($2.8 Mil) to Dec. 2020 ($4.3 Mil).


Flexion Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Flexion Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flexion Therapeutics Inventories, Raw Materials & Components Chart

Flexion Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.93 2.37 2.85 4.29

Flexion Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.86 4.29 4.39 3.57 2.83

Flexion Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Flexion Therapeutics (Flexion Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
10 Mall Road, Suite 301, Burlington, MA, USA, 01803
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.
Executives
Mark S. Levine officer: General Counsel 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Kerry Wentworth officer: Chief Regulatory Officer AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Christina Willwerth officer: Chief Strategy Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803
David Arkowitz officer: Chief Financial Officer C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Melissa Layman officer: Chief Commercial Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803
Scott Kelley officer: Chief Medical Officer C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael D. Clayman director, officer: President and CEO C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Alan Milinazzo director C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
C Ann Merrifield director
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Samuel D Colella director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Patrick J Mahaffy director C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Mark Stejbach director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403

Flexion Therapeutics (Flexion Therapeutics) Headlines

From GuruFocus